InvestorsHub Logo

Here Today

08/14/21 11:47 AM

#370415 RE: Bad_Timing #370414

In my opinion, Priceless....

Jhawker

08/14/21 12:01 PM

#370417 RE: Bad_Timing #370414

Or in conjunction with immunotherapy? Currently about 20% of people respond to immunotherapy and the industry is frantically looking to boost that %.

sunspotter

08/14/21 12:09 PM

#370419 RE: Bad_Timing #370414

“Some wishful thinking while we wring our hands waiting for results.”

Be careful what you wish for.

It is the fact that brilacidin is mimicking a cationic AMP that makes it distinctly possible that its MoA in vitro is due to phospholipidosis, which would mean it’s unlikely to work in vivo.

xoc

08/14/21 12:17 PM

#370420 RE: Bad_Timing #370414

Article on use of defensin as antineoplastic



https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537071/

williamssc

08/14/21 1:28 PM

#370422 RE: Bad_Timing #370414

It's reassuring and gives hope knowing past phase 2 clinical trials have been successful.